Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-25 @ 2:38 AM
NCT ID:
NCT05484934
Eligibility Criteria:
Inclusion Criteria:
* General Criteria:
* Females age \>18 and \<65 years old. Women of childbearing potential must agree to use an acceptable method of contraception for one month prior to DCLNAC implantation, and until the graft is 100% healed. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap. Nonchildbearing potential for women is defined as postmenopausal (last natural menses greater than 12 months) or undergone a documented bilateral tubal ligation or hysterectomy. If last natural menses less than 12 months, a serum FSH value confirming post-menopausal status can be employed.
* Patient agrees to sleep on back until study tissue products are healed
* Patient agrees to abstain from aspirin, alcohol, or excessive caffeine until study tissue products are healed
* Patient agrees to not undergo NAC tattooing until completing study
* Patient can understand and willing to sign informed consent
* Patient desires bilateral nipple reconstruction with DCLNAC
* Subjects must be capable of providing written informed consent to the study procedures and for use of protected health information \[Health Insurance Portability and Accountability Act (HIPAA), if applicable\]
* Specific Criteria
Group A:
* Patient had a bilateral mastectomy with no radiation therapy
* Patient has undergone a bilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study
Group B:
* Patient had a unilateral mastectomy with no radiation therapy
* Patient has undergone a unilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study
Group C:
* Patient had a bilateral mastectomy and received radiation unilaterally
* Patient has undergone a bilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study
Group D:
\- Patient had unilateral or bilateral mastopexy (with or without augmentation) or reduction mammaplasty and suffered nipple complications (i.e., necrosis, projection loss)
Group E:
* Patient had unilateral or bilateral mastectomy
* Patient had unilateral or bilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study
* Patient did not receive radiation to the autologously reconstructed breast
* Patient had unilateral or bilateral nipple reconstruction that failed (i.e., necrosis, projection loss)
Group F:
\- Implant based reconstruction
Exclusion Criteria:
* Patient has a history of delayed wound healing
* Patient has a history of Vitamin C deficiency
* BMI\<18.5 or \>40 kg/m2
* Patient has a history of allergic reaction to any decellularized biologic matrix product
* Patient is currently smoking or using tobacco or nicotine products (i.e., patch, gum, vaping or nasal spray) or has used such products in the past 6 months
* Patient is currently receiving bilateral breast radiation or completed less than 3 months prior to screening
* Patient has any systemic disease that would impede wound healing, such as diabetes or connective tissue disorders
* Patient is pregnant, breastfeeding or planning to become pregnant during the study period
* Patient has any type of disease or disorder that in the investigator's opinion would make the patient unfit for the study, including active infection anywhere in the body.
* Acute mastitis in either breast
* History of an autoimmune disorder
* Use of any medications currently or in the past 3 months that would impair wound healing, such as long-term use of systemic steroids (inhaled, limited topical, short-term oral use and intra-articular steroids are acceptable)
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT05484934
Study Brief:
Protocol Section:
NCT05484934